TRANSFUSION SUPPORT--CORE

输血支持--核心

• 批准号: 3805850
• 负责人: WILLIAM I BENSINGER
• 金额: --
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3805850
• 关键词: antileukocyte isoantibody; biomedical facility; blood donor; bone marrow transplantation; cell mediated cytotoxicity; cytomegalovirus; data collection; histocompatibility; histocompatibility typing; platelet transfusion; plateletpheresis

The success of marrow transplantation is heavily dependent on the transfusion of blood products and is a situation which provides many opportunities for research in transfusion immunology. In Project IX we have described our research proposals for problems of platelet alloimmunization. In Project III we describe our proposals for the utilization of blood products screened for antibody to cytomegalovirus (CMV) as well as an evaluation of leukocyte-depleted blood products for the prevention of CMV. In this core section we are concerned with mechanisms for deriving research information from clinically necessary transfusion support and plasma modification procedures. We ask support only for key personnel for supervision and data entry where we cannot recover costs from charges but where the work is essential to carrying out the proposed research in individual program projects. These areas include establishing and maintaining data bases containing detailed descriptive information on all blood product transfusions and on the course and outcome of all ABO-incompatible transplants requiring plasma modification or marrow red cell depletion.

骨髓移植的成功很大程度上取决于 输注血液制品是一种提供 输血免疫学研究有很多机会。 在 项目 IX 我们已经描述了我们针对问题的研究建议 血小板同种免疫。 在项目 III 中，我们描述了我们的 关于使用经过筛选的血液制品的建议 巨细胞病毒（CMV）抗体以及评估 用于预防 CMV 的去白细胞血液制品。 在 在这个核心部分，我们关注的是派生机制 来自临床必要的输血支持的研究信息 和等离子体改性程序。 我们仅要求关键支持 我们无法恢复的监督和数据输入人员 费用来自收费，但工作对于开展工作至关重要 个别计划项目中拟议的研究。 这些领域 包括建立和维护数据库，其中包含 所有血液制品输注的详细描述信息 以及所有 ABO 不相容的过程和结果 需要血浆修饰或骨髓红细胞的移植 消耗。